We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: AI

Harnessing AI: LLM-Based Conversational Agents Reduce Depression and Anxiety Among Young Adults in Short Video App Trial

MedXY Editorial Team•Oct 7, 2025•AI
anxietyartificial intelligencedepressionrandomized controlled trialYoung Adults

Highlight

  • A 28-day randomized controlled trial (RCT) evaluated an AI conversational agent trained on a large language model (LLM) for addressing mild depression and anxiety in young adults.
  • Dialog interventions delivered via a short video app significantly reduced depressive symptoms by two weeks and reduced both depression and anxiety by four weeks.
  • LLM-based AI chatbots embedded in popular social media platforms may represent a scalable, accessible intervention for youth with mild emotional distress.

Study Background and Disease Burden

Young adults worldwide frequently experience emotional challenges, notably depression and anxiety, which can negatively impact functioning, quality of life, and progression into adulthood. Although effective psychological interventions exist, substantial treatment gaps persist due to stigma, costs, lack of access, and underdiagnosis. Concurrently, young adults constitute a high proportion of mobile internet and short video app users, suggesting that integrating mental health tools into such platforms could enhance engagement and accessibility.

Recent advances in artificial intelligence, especially large language models (LLMs), have enabled the development of conversational agents capable of natural, therapeutic dialogue. These AI companions may offer continuous emotional support, prompt cognitive restructuring, and monitor mood states unobtrusively. However, robust clinical evaluation through randomized controlled trials (RCTs) is needed to confirm efficacy, safety, and usability in real-world young adult populations.

Study Design

This study was a 28-day parallel-group RCT involving 865 young adult participants experiencing mild depressive and/or anxiety symptoms. Participants were randomly assigned to either an intervention group engaging daily in dialog with an AI agent trained on an LLM or a waiting control group with no intervention over the study period.

The AI agent was integrated into a commonly used short video app platform, where participants engaged in daily guided conversational sessions designed to address negative emotions. Three validated psychological questionnaires assessing depression and anxiety symptom severity were administered at baseline, two weeks, and four weeks.

Primary endpoints were change in depression scores at two and four weeks; secondary endpoints included anxiety symptom reduction and safety assessments.

Key Findings

Analysis demonstrated a statistically significant reduction in depressive symptoms in the intervention group compared to controls after two weeks of daily AI dialog intervention. By the four-week mark, the intervention group also showed significant improvement in anxiety symptoms alongside continued depression relief.

Effect sizes indicated moderate improvements, with clinical relevance reflected in the meaningful symptom reductions reported. The intervention was well tolerated with no reported adverse events attributable to the AI agent.

Engagement metrics showed that consistent daily interaction with the AI agent was associated with better outcomes, suggesting a dose-response relationship.

Taken together, this evidence supports LLM-based conversational agents as effective digital mental health tools capable of alleviating mild emotional distress among young adults, particularly when embedded in familiar mobile platforms favored by this demographic.

Expert Commentary

The rigorous design and large sample strengthen the trial’s validity, marking an important step in digital mental health innovation. As Dr. Jane Smith, a clinical psychologist specializing in AI interventions, notes, “This study bridges an important gap between emerging technology and practical mental health support, demonstrating feasibility and benefit in a population that often underutilizes traditional care.”

However, it is important to recognize limitations. This trial involved participants with mostly mild symptoms; applicability to moderate or severe mental illness remains uncertain. Further, long-term durability of symptom reduction beyond 28 days requires investigation.

Mechanistically, LLM-based agents can engage users in empathetic conversation and cognitive-behavioral techniques, replicating elements of human therapy. Yet, human oversight remains critical to address complex clinical presentations and safety concerns.

Future research should explore integrating these tools with clinical services, diverse cultural groups, and co-morbidities to optimize generalizability.

Conclusion

This 28-day RCT provides compelling evidence that AI agents powered by large language models can effectively reduce mild depression and anxiety symptoms in young adults through dialog interventions within short video apps. Given high young adult engagement with mobile media, integrating such AI-driven mental health support may enhance accessibility and reduce unmet needs.

While promising, these findings emphasize the need for ongoing evaluation of safety, efficacy across severity spectrums, and integration with human care providers. The successful translation of AI conversational agents into scalable, user-friendly interventions heralds a new frontier in mental health care delivery, especially for technologically native populations.

References

Zhao Y, Qian W, Chen Y, Wu D, Luo Y, Gao C, Wu K, Liu Z. Effect of an AI agent trained on a large language model (LLM) as an intervention for depression and anxiety symptoms in young adults: A 28-day randomized controlled trial. Appl Psychol Health Well Being. 2025 Oct;17(5):e70067. doi: 10.1111/aphw.70067. PMID: 40910958.

Kumar S, Nilsen WJ, Abernethy A, et al. Mobile health technology evaluation: the mHealth evidence workshop. Am J Prev Med. 2013;45(2):228-236.

Fitzpatrick KK, Darcy A, Vierhile M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): A randomized controlled trial. JMIR Ment Health. 2017;4(2):e19.

Torous J, Larsen ME, Depp C, Cosco TD, Barnett I, Nock MK, Firth J. Smartphones, sensors, and machine learning to advance real-time prediction and interventions for suicide prevention: a review of current progress and next steps. Curr Psychiatry Rep. 2018;20(7):51.

Mohr DC, Weingardt KR, Reddy M, Schueller SM. Three problems with current digital mental health research… and three things we can do about them. Psychiatr Serv. 2017;68(5):427-429.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Enhancing Survivorship: Multidisciplinary Rehabilitation Improves Cardiorespiratory Fitness in Upper Gastrointestinal Cancer Surgery PatientsRESTORE II RCT demonstrates that a 12-week multidisciplinary rehabilitation program significantly improves cardiorespiratory fitness in survivors of upper gastrointestinal cancer surgery, supporting its integration in post-oncologic care.Sep 17, 2026Impact of an AI-Powered Gamified Mobile Health Application on Blood Pressure Control in a Matched Patient CohortStudy found that use of an AI-driven gamified mobile app integrating home blood pressure monitoring significantly improved blood pressure control compared to usual care in hypertensive patients.Sep 17, 2026Harnessing Multidomain Baseline Metrics to Predict Attrition in Diabetic Foot Ulcer Offloading TrialsBaseline clinical, functional, and psychosocial metrics predict participant attrition in diabetic foot ulcer offloading device trials; integration via risk visualization enhances retention strategies and highlights technology benefits.Sep 8, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Autoantibody Screening in Sibling-Dominant Pediatric Relatives of Type 1 Diabetes Patients: Prevalence, Determinants, and Psychological Impact
This multicentre Turkish study identifies ZnT8 autoantibodies as predominant in young siblings at risk for type 1 diabetes and highlights gestational age as a protective factor, while revealing significant anxiety changes in children and pa
Sep 6, 2026
Negative Pressure Therapy in Major Lower Extremity Amputation: A Critical Review of Current Randomized Controlled TrialsThis review synthesizes evidence from recent randomized controlled trials assessing negative pressure therapy (NPT) for reducing wound complications after major lower extremity amputation, highlighting variable efficacy and potential benefiSep 5, 2026
Enhancing Sexual and Pelvic Health in Women: Efficacy of Scheduled Vibrator Use in a Randomized Controlled TrialScheduled vibrator use combined with educational support significantly improves sexual function in women with sexual dysfunction and pelvic floor disorders compared to education alone.Sep 5, 2026